Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

NCT07235176 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced ER+/HER2- Breast Cancer

Interventions

DRUG: QLS1304 tablet+Fulvestrant or QLC1401
DRUG: QLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i

Sponsor

Qilu Pharmaceutical Co., Ltd.